4 days ago
Argenx added to Best Ideas List at Wedbush
Wedbush added Argenx (ARGX) to the firm's Best Ideas List as it believes the company is uniquely positioned to deliver sustained, market-leading growth in the autoimmune space, driven by continued expansion of Vyvgart and an emerging pipeline of assets that can sustain long-term momentum. Wedbush has an Outperform rating on the shares with a price target of $715.
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ARGX:
Disclaimer & DisclosureReport an Issue
Argenx pullback brings 'attractive buying opportunity,' says Citi
Argenx Se: Strong Growth Prospects and Attractive Buying Opportunity Amid Vyvgart Expansion and Upcoming Catalysts
Argenx price target lowered to $699 from $701 at Citizens JMP
Argenx upgraded to Outperform from Neutral at Baird
Argenx Se: Buy Rating Affirmed Amid Pricing Strategy Confidence and Promising Growth Prospects
